Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Private equity firm jumps into vascular health with new investment
Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.
New report raises questions about data that helped heart drug gain FDA approval
Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
Angiographic catheters recalled due to safety risk
The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.
FDA clears blood clot removal system for treating pulmonary embolism
The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE study were published in JSCAI.

healthcare money economics dollar stethoscope acquire merger

Private equity firm jumps into vascular health with new investment

Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.

New report raises questions about data that helped heart drug gain FDA approval

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

Cook Medical angiographic catheter recall

Angiographic catheters recalled due to safety risk

The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.

Inquis Medical Aventus Thrombectomy System

FDA clears blood clot removal system for treating pulmonary embolism

The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE study were published in JSCAI.

milli-spinner thrombectomy designed to target blood clots by engineers with Stanford University

Tiny clot-busting robots could transform care for stroke and heart attack patients

The robots are capable of swimming through a patient’s vascular system and removing blood clots. “It’s unbelievable," one Stanford researcher said. "This is a sea-change technology that will drastically improve our ability to help people.”

Reflow Medical Spur Peripheral Retrievable Stent System

New-look peripheral stent with expandable spikes receives FDA’s de novo classification

California-based Reflow Medical gained the approval after submitting data from the DEEPER REVEAL clinical trial. The device was associated with a high success rate and improved outcomes in CLTI patients.

Terumo Interventional Systems launches dual-layer micromesh carotid stent after FDA approval

The dual-layer micromesh stent was designed with the flexibility of an open-cell stent and is available in multiple sizes.